Placeholder Banner

Canadian patent strengthens IP for Allon’s 2nd technology platform

October 9, 2009
Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a Canadian patent covering the chemical composition of the Company’s preclinical-stage peptide AL-209 and its use in protecting against Alzheimer’s disease and other degenerative diseases. The Company said AL-209 has demonstrated highly potent neuroprotective activity in preclinical studies where it has been shown to block the effect of toxic insults and protect against neuronal cell death. AL-209 comes from the same Activity-dependent neurotrophic factor (ADNF) platform as AL-309 and has significant potential across a range of disease indications.